Omeros’ (OMER) “Buy” Rating Reiterated at HC Wainwright

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $40.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 178.16% from the company’s previous close.

Several other analysts have also commented on OMER. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Price Performance

Shares of OMER stock opened at $14.38 on Thursday. The stock’s fifty day simple moving average is $12.22 and its 200 day simple moving average is $11.35. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -28.76 and a beta of 2.66. Omeros has a one year low of $2.95 and a one year high of $17.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.16. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $10.05 million. On average, research analysts anticipate that Omeros will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

Institutional investors have recently bought and sold shares of the business. State of Wyoming bought a new position in Omeros in the 4th quarter valued at $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros in the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros in the 4th quarter valued at $33,000. Assetmark Inc. bought a new position in Omeros in the 1st quarter valued at $38,000. Finally, Tower Research Capital LLC TRC raised its position in Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.